Small Cell Lung Cancer Therapeutics Market Forecast to Reach $10.87 Billion by 2028 Amid Advances in Early Detection and Treatment Dublin, Feb. 19, 2024 (GLOBE NEWSWIRE) -- The "Small Cell Lung Cancer Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Growth in Small Cell Lung...

Analysis of AstraZeneca's IMFINZI (Durvalumab) for Treating Malignant Pleural Mesothelioma (MPM): Regulatory Landmarks, Market Expansion, Intellectual Property, Future Challenges - Forecast to 2032 Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "IMFINZI Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This comprehensive report...

Extensive Stage Small Cell Lung Cancer Global Market Report 2022: Next-Generation Sequencing is Helping in Identifying New Molecular Targets Dublin, Dec. 14, 2022 (GLOBE NEWSWIRE) -- The "Extensive Stage Small Cell Lung Cancer Market - A Global and Regional Analysis: Focus on Epidemiology, Product, and Region - Analysis and Forecast,...

Global Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast 20202030 Dublin, Oct. 09, 2020 (GLOBE NEWSWIRE) -- The "Programmed Death-Ligand 1 (PD-L1) Non-Small Cell Lung Cancer (NSCLC)-Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been...

Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016 TUSTIN, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...